Abstract:Objective To observe the efficacy and safety of LiShenBao (uFSH) in the treatment of severe oligoasthenospermia. Methods Using a multi-centered, open and self-controlled clinical trial, we treated 43 patients with severe oligoasthenospermia with LiShenBao 75 IU/3d, i.m, for 24 weeks, and evaluated the the semen parameters including sperm concentration and the percentage of progressive motile sperm, reproductive hormone, adverse reaction and pregnancy condition of their spouse at 8, 16 and 24 weeks. Results Compared with baseline, the sperm concentration was increased by 334%, 258% and 460% respectively at 8, 16 and 24 weeks, elevating from the baseline of (1.39±1.58)×106/mL to(7.79±8.44)×106/mL at 24 weeks. The percentage of progressive motile sperm was significantly improved (increased by 71%, 135% and 143% respectively at 8, 16 and 24 weeks). There was also an increase in terms of sperm motility and total number, and serum FSH, while no significant changes were observed in sperm volume, LH and T. One patient with severe oligoasthenospermia has pregnancy during the treatment. Conclusion LiShenBao can evidently improve the seminal quality of oligoasthenospermic patients with no obvious adverse events.

Multi-center clinical trial of LiShenBao (uFSH) in the treatment of severe oligoasthenospermia